PROSTATENOW™  Why test?

The Next Generation of Hereditary Cancer Testing

The genetics of prostate cancer.

Inherited factors account for 57% of the risk for developing prostate cancer. The heritability of prostate cancer is stronger compared to other cancers such as breast cancer, ovarian cancer and colorectal cancer. This highlights the importance of assessing the inherited risk for prostate cancer.

PROSTATENOW™ is the only test today that assesses a patient’s risk based on all three methods:

Mask-Group-29@2x

Family History (FH)

FH is a common but indirect measurement of inherited risk.

Men with a positive FH have a 1.5-to-2.5-fold increased risk for developing prostate cancer.

 
Group-6846@2x (1)

Rare Pathogenic Mutations (RPMs)

RPMs are pathogenic DNA mutations in the coding regions of genes such as BRCA2, ATM, and CHEK2.

RPMs are associated with a moderate-to-high risk 
for developing prostate cancer. Also associated with prostate cancer aggressiveness.

Group-6846@2x 2

Genetic Risk Score (GRS)

Calculated based on more than 100 single nucleotide polymorphisms (SNPs) associated with prostate cancer risk.

Used to assess a man’s risk of developing prostate cancer compared to other men in the general population.